Article

FDA Approves Preservative-Free Ophthalmic Solution for Eye Allergy Itch

Author(s):

Ketotifen fumarate ophthalmic solution 0.035% is the first and only over-the-counter preservative-free eye drop solution for itchy eyes caused by allergies.

FDA

The US Food and Drug Administration (FDA) has approved ketotifen fumarate ophthalmic solution 0.035% (Alaway) antihistamine eye drops (EM-100) as the first over-the-counter preservative-free formulation eye drop for the treatment of itchy eyes caused by allergies.

The approval, granted to Bausch + Lomb and Eton Pharmaceuticals, is indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children ≥3 years.

About 80% of people with allergies experience itchy eyes as one of their symptoms. Preservatives that are commonly used in eye drops can lead to an allergic reaction, thus causing redness, irritation, itching, or tearing.

Alaway has been formulated to relieve eye itch within minutes. Furthermore, with only 1 dose, the eye drop is able to provide up to 12 hours of relief.

"We are pleased the FDA has approved Alaway Preservative Free, and we look forward to collaborating with Bausch + Lomb to bring this unique eye drop to patients suffering from itchy eyes associated with eye allergies," said Sean Brynjelsen, CEO of Eton Pharmaceuticals, in a statement.

According to Joe Gordon, the US president of Bausch + Lomb, the ophthalmic solution is anticipated to reach the market by Spring 2021, in time for the onset of allergy season.

Related Videos
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Monica Kraft, MD: Discussing Phase 3b Findings on Albuterol/Budesonide for Asthma
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
© 2024 MJH Life Sciences

All rights reserved.